Relmada Therapeutics Appoints Chief Business Officer

What Happened

• Relmada Therapeutics, Inc. announced on July 28, 2026 that Bipin Dalmia, PhD, MBA has been appointed as the Company’s Chief Business Officer. The company issued a press release announcing the appointment and furnished that press release under Regulation FD in a Form 8-K filed July 28, 2026.

Key Details

• Appointee: Bipin Dalmia, PhD, MBA named Chief Business Officer.
• Disclosure date: Press release issued and Form 8-K furnished on July 28, 2026.
• Regulatory note: The press release was furnished as Exhibit 99.1 under Regulation FD and is designated as furnished (not “filed”) for Section 18 purposes.

Why It Matters

• This 8-K documents an executive leadership change; investors typically watch such appointments because they relate to how the company pursues business development, partnerships and commercial strategy. The filing contains the press release only and does not disclose additional material financial information, agreements, or compensation details.